Literature DB >> 10578130

Efficient functional coupling of the human D3 dopamine receptor to G(o) subtype of G proteins in SH-SY5Y cells.

P G Zaworski1, G L Alberts, J F Pregenzer, W B Im, J L Slightom, G S Gill.   

Abstract

1 The D3 dopamine receptor presumably activates Gi/Go subtypes of G-proteins, like the structurally analogous D2 receptor, but its signalling targets have not been clearly established due to weak functional signals from cloned receptors as heterologously expressed in mostly non-neuronal cell lines. 2 In this study, recombinant human D3 receptors expressed in a human neuroblastoma cell line, SH-SY5Y, produced much greater signals than those expressed in a human embryonic kidney cell line, HEK293. Quinpirole, a prototypic agonist, markedly inhibited forskolin-stimulated cyclic AMP production and Ca2+-channel (N-type) currents in SH-SY5Y cells, and enhanced GTPgamma35S binding in isolated membranes, nearly ten times greater than that observed in HEK293 cell membranes. 3 GTPgamma35S-bound Galpha subunits from quinpirole-activated and solubilized membranes were monitored upon immobilization with various Galpha-specific antibodies. Galphao subunits (not Galphai) were highly labelled with GTPgamma35S in SH-SY5Y, but not in HEK293 cell membranes, despite their abundance in the both cell types, as shown with reverse transcription-polymerase chain reaction and Western blots. N-type Ca2+ channels and adenylyl cyclase V (D3-specific effector), on the other hand, exist only in SH-SY5Y cells. 4 More efficient coupling of the D3 receptor to Go subtypes in SH-SY5Y than HEK293 cells may be attributed, at least in part, to the two D3 neuronal effectors only present in SH-SY5Y cells (N-type Ca2+-channels and adenylyl cyclase V). The abundance of Go subtypes in the both cell lines seems to indicate their availability not a limiting factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10578130      PMCID: PMC1571750          DOI: 10.1038/sj.bjp.0702905

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Cloning and expression of an adenylyl cyclase localized to the corpus striatum.

Authors:  C E Glatt; S H Snyder
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

Review 2.  Molecular diversity of the dopamine receptors.

Authors:  O Civelli; J R Bunzow; D K Grandy
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

3.  Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.

Authors:  L Tang; R D Todd; A Heller; K L O'Malley
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

4.  Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors.

Authors:  C Chabert; C Cavegn; A Bernard; A Mills
Journal:  J Neurochem       Date:  1994-07       Impact factor: 5.372

5.  Functional expression and characterization of human D2 and D3 dopamine receptors.

Authors:  M N Potenza; G F Graminski; C Schmauss; M R Lerner
Journal:  J Neurosci       Date:  1994-03       Impact factor: 6.167

6.  Inversion of Ca2+ current modulation during recovery of neuroblastoma cells from pertussis toxin pretreatment.

Authors:  P Friederich; B Nürnberg; G Schultz; J Hescheler
Journal:  FEBS Lett       Date:  1993-11-22       Impact factor: 4.124

7.  Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.

Authors:  C L Chio; M E Lajiness; R M Huff
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

8.  Expression and pharmacological characterization of the human D3 dopamine receptor.

Authors:  S B Freedman; S Patel; R Marwood; F Emms; G R Seabrook; M R Knowles; G McAllister
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

9.  U-92032, a T-type Ca2+ channel blocker and antioxidant, reduces neuronal ischemic injuries.

Authors:  C Ito; W B Im; H Takagi; M Takahashi; K Tsuzuki; S Y Liou; M Kunihara
Journal:  Eur J Pharmacol       Date:  1994-05-23       Impact factor: 4.432

10.  Characterization of the human dopamine D3 receptor expressed in transfected cell lines.

Authors:  R G MacKenzie; D VanLeeuwen; T A Pugsley; Y H Shih; S Demattos; L Tang; R D Todd; K L O'Malley
Journal:  Eur J Pharmacol       Date:  1994-01-01       Impact factor: 4.432

View more
  14 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 3.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 5.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

6.  Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.

Authors:  Martyn Wood; Vanessa Dubois; Dieter Scheller; Michel Gillard
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

7.  Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.

Authors:  Amy Hauck Newman; Thijs Beuming; Ashwini K Banala; Prashant Donthamsetti; Katherine Pongetti; Alex LaBounty; Benjamin Levy; Jianjing Cao; Mayako Michino; Robert R Luedtke; Jonathan A Javitch; Lei Shi
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

8.  Cell type influences the molecular mechanisms involved in hormonal regulation of ERG K+ channels.

Authors:  Luis Carretero; Francisco Barros; Pablo Miranda; Jorge Fernández-Trillo; Angeles Machín; Pilar de la Peña; Pedro Domínguez
Journal:  Pflugers Arch       Date:  2012-03-14       Impact factor: 3.657

9.  Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells.

Authors:  G L Alberts; J F Pregenzer; W B Im
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

10.  Functional coupling between heterologously expressed dopamine D(2) receptors and KCNQ channels.

Authors:  Trine Ljungstrom; Morten Grunnet; Bo Skaaning Jensen; Søren-Peter Olesen
Journal:  Pflugers Arch       Date:  2003-06-21       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.